← Back to Search

Excimer Laser

Topography-guided LASIK for Near-sightedness

Phase 3
Waitlist Available
Research Sponsored by Clinical Research Consultants, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This purpose of this study is to evaluate the safety and effectiveness of a topography-based custom ablation treatment using the ALLEGRETTO WAVE® Eye-Q 400 Hz laser system for treating myopia and hyperopia.

Eligible Conditions
  • Near-sightedness
  • Farsightedness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From undefined Phase 3 trial • 212 Patients • NCT01028378
1%
BSCVA loss of 2 or more lines
1%
Retinal Detachments
100%
80%
60%
40%
20%
0%
Study treatment Arm
Topography-guided LASIK

Trial Design

1Treatment groups
Experimental Treatment
Group I: Topography-guided LASIKExperimental Treatment1 Intervention
Topography-guided LASIK for Myopia or Hyperopia
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
2009
Completed Phase 3
~220

Find a Location

Who is running the clinical trial?

Clinical Research Consultants, Inc.Lead Sponsor
6 Previous Clinical Trials
1,192 Total Patients Enrolled
WaveLight AGIndustry Sponsor
1 Previous Clinical Trials
144 Total Patients Enrolled
Alcon ResearchIndustry Sponsor
728 Previous Clinical Trials
128,842 Total Patients Enrolled
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top